Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

George Evans

Family Medicine Sheffield, AL Medical Doctor

NPI 1124073788 CMS profile 141293

342 Cox Blvd, Sheffield, AL 35660

Open in the dashboard

General payments

$16,061

909 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, George Evans of Sheffield, AL is reported in the CMS Open Payments database as having received $16,061 across 909 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,939 113
2024 General $2,402 149
2023 General $1,667 120
2022 General $1,993 143
2021 General $2,726 147
2020 General $2,822 134
2019 General $2,512 103

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Evans
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to George Evans were reported at $1,939. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year George Evans Family Medicine median Middle half National median
2019 $2,512 $150 $41–$543 $163
2020 $2,822 $120 $32–$415 $114
2021 $2,726 $137 $35–$551 $132
2022 $1,993 $137 $37–$512 $149
2023 $1,667 $149 $42–$545 $160
2024 $2,402 $156 $44–$560 $164
2025 $1,939 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $2,374 112 payments
  2. AstraZeneca Pharmaceuticals LP $1,433 53 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,315 102 payments
  4. AbbVie, Inc. $1,115 124 payments
  5. Amarin Pharma Inc. $1,080 55 payments
  6. GlaxoSmithKline, LLC. $927 47 payments
  7. Pfizer Inc. $686 46 payments
  8. Lilly USA, LLC $626 48 payments
  9. Amgen Inc. $456 14 payments
  10. Esperion Therapeutics, Inc. $444 17 payments
  11. Other $5,606 291 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,031 903 payments
  2. Education $30 5 payments
  3. Gift $0 1 payment
Products named General payments · program years 2019–2025
  1. RYBELSUS $1,070 51 payments
  2. Ozempic $1,059 68 payments
  3. RELISTOR Gastroenterology $984 81 payments
  4. RELISTOR Gastroenterology $916 74 payments
  5. Vascepa $874 44 payments
  6. TRELEGY ELLIPTA $806 45 payments
  7. FARXIGA $694 21 payments
  8. UBRELVY $535 70 payments
  9. QULIPTA $502 56 payments
  10. NEXLETOL $444 17 payments
  11. Other $12,455 704 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 124 billing codes

Paid by Medicare

$112,737

Of which drugs: $1,700

Medicare patients

185

Average age 70

Services billed

29,932

93 women, 92 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 40%
Arthritis 40%
Ischemic heart disease 21%
Chronic kidney disease 19%
COPD 19%
Osteoporosis 13%
Depression 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from cell cultures 90661 Office 20 20 $686
Injection, methylprednisolone acetate, 1 mg J1010 Office 26 3,560 $347
Injection, ketorolac tromethamine, per 15 mg J1885 Office 18 118 $64
Injection, methylprednisolone acetate, 80 mg J1040 Office 14 17 $61
Injection, ceftriaxone sodium, per 250 mg J0696 Office 13 60 $17

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

909 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record